Longeveron Inc. cash flow statement

In fiscal 2025, Longeveron Inc.'s operations generated −$18.6m of cash; it spent $245,000 on capital projects, leaving free cash flow of −$18.9m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Longeveron Inc.: cash flow statement, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash from operations	−2	−10	−14	−19	−14	−19	−20
Depreciation and amortisation	0	0	1	1	1	1	1
Stock-based pay	0	1	2	2	2	2	2
Capital spending	0	0	1	0	1	0	0
Free cash flow	−2	−10	−15	−19	−15	−19	−21
Free cash flow after stock pay	−3	−11	−17	−21	−17	−21	−22
Shares issued	—	27	0	5	13	5	—

US$ thousands unless shown otherwise. Fiscal quarters.

Longeveron Inc.: cash flow statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Cash from operations	−2,843	−3,373	−4,697	−3,597	−5,055	−5,296	−4,370	−5,653
Depreciation and amortisation	200	200	200	200	200	200	200	200
Stock-based pay	1,413	390	340	513	448	376	379	373
Capital spending	430	13	27	161	57	0	0	103
Free cash flow	−3,273	−3,386	−4,724	−3,758	−5,112	−5,296	−4,370	−5,756
Free cash flow after stock pay	−4,686	−3,776	−5,064	−4,271	−5,560	−5,672	−4,749	−6,129
Shares issued	8,144	0	—	—	—	836	—	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: DARE vs LGVN LGVN vs STTK LGVN vs RNAC LGVN vs MNOV

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Longeveron Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Longeveron Inc.